Hypermobility syndrome (HM) or benign joint hypermobility syndrome (BJHS) is a hereditary connective tissue disorder seen in the pediatric age group. Some authors have defined joint hypermobility syndrome (JHS) as a condition which includes individuals with hypermobile joints accompanied by symptoms of unknown etiology [1] [2] [3]. Other authors state that hereditary connective tissue disorders may be associated with JHS and "benign JHS" are used to differentiate it from other more life-threatening connective tissue disorders like Ehlers Danlos syndrome (EDS), Marfan syndrome, and Loeys Dietz syndrome [4]. According to Simpson [5], JHS is currently considered an inherited connective tissue disorder with features similar to those of Marfan syndrome and Ehlers Danlos syndrome type 3, hypermobility type.

Hypermobility syndrome is transmitted in an autosomal pattern. The penetrance is variable [6] with a majority of the patients having no identifiable collagen protein abnormalities although a few may have a deficiency of tenascin-X [5]. There is often a family history of the syndrome.

Although symptoms can start at any age, they are typically noticed in childhood and adolescence. Females are affected more than males. The presenting complaint is usually severe, debilitating pain, which is aggravated by activity e.g pain in the lower limbs while walking or difficulty writing in school. Children report "cracking" joints, swelling in the joints (especially knees and ankles) lasting for several days, recurrent joint subluxations or dislocations which reduce spontaneously. Exercise, excessive movement and joint stress are believed to cause the chronic joint pain. A backache is another common symptom, especially in the lumbar region as it is the most mobile part of the vertebral column. Other common symptoms include myalgia, cramps, and stiffness of the joints [7]. Affected patients claim to be double jointed and can voluntarily subluxate.

The condition is often misdiagnosed as young children normally have an extensive range of motion at all their joints. The "Beighton score" has been used to diagnose hypermobility but the scores are variable depending on investigators. So currently the Villefranche classification [8] which includes clinical signs, family history, major and minor criteria is used for diagnosis. The major criteria are joint hyperlaxity, skin hyperextensibility, and no evidence of skin or soft tissue fragility. The minor criteria are a family history of the syndrome, recurrent joint instability, and the ability to bruise easily. Limitation of the Villefranche classification is that it does not account for extra-musculoskeletal manifestations.

The workup depends upon a detailed patient history, family history of joint hypermobility syndrome and thorough physical examination to look for hypermobile joints and signs of tissue fragility. Genetic testing may be useful in the diagnosis of the syndrome. Radiograph findings include small calcifications in the subcutaneous tissues. Magnetic resonance imaging can help to detect white matter lesions [9].

As gene mutations have not been identified as yet, prenatal testing cannot be recommended. However genetic counseling should be considered if there is a family history.

Treatment for Hypermobility Syndrome focuses on managing symptoms and improving quality of life. Physical therapy is often recommended to strengthen muscles and stabilize joints. Pain management may include medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics. In some cases, braces or orthotics may be used to support unstable joints. Lifestyle modifications, such as avoiding activities that exacerbate symptoms, are also important.

The prognosis for individuals with Hypermobility Syndrome varies. Many people can manage their symptoms effectively with appropriate treatment and lifestyle adjustments. However, some may experience chronic pain and recurrent joint issues. The condition is generally not progressive, meaning it does not worsen over time, but symptoms can fluctuate. Early diagnosis and intervention can improve outcomes and help individuals maintain an active lifestyle.

The exact cause of Hypermobility Syndrome is not fully understood, but it is believed to have a genetic component. It often runs in families, suggesting a hereditary link. The condition is thought to result from abnormalities in collagen, a protein that provides structure and strength to connective tissues. These abnormalities can lead to increased elasticity in ligaments and tendons, resulting in hypermobile joints.

Hypermobility Syndrome is relatively common, affecting approximately 10-20% of the general population. It is more prevalent in females and tends to be more common in children and adolescents. The prevalence decreases with age as joint flexibility naturally declines. Certain ethnic groups, such as those of African or Asian descent, may have higher rates of hypermobility.

The pathophysiology of Hypermobility Syndrome involves the connective tissues, which include ligaments, tendons, and skin. In individuals with HMS, these tissues are more elastic than normal due to alterations in collagen. This increased elasticity allows joints to move beyond their typical range, leading to instability and potential damage. Over time, repeated stress on hypermobile joints can cause pain and other musculoskeletal issues.

There is no known way to prevent Hypermobility Syndrome, as it is largely genetic. However, individuals with hypermobility can take steps to minimize symptoms and prevent complications. Regular exercise, particularly activities that strengthen muscles and improve joint stability, can be beneficial. Avoiding high-impact sports and activities that place excessive strain on joints is also recommended. Education on proper body mechanics and posture can help reduce the risk of injury.

Hypermobility Syndrome is a condition characterized by joints that move beyond the normal range of motion, often leading to pain and other symptoms. While the exact cause is not fully understood, it is believed to have a genetic component related to collagen abnormalities. Diagnosis involves clinical evaluation and the use of tools like the Beighton score. Treatment focuses on symptom management through physical therapy, pain relief, and lifestyle modifications. The condition is common and varies in severity, but with proper management, individuals can lead active lives.

If you have been diagnosed with Hypermobility Syndrome, it's important to understand that while the condition can be challenging, there are effective ways to manage it. Working with healthcare professionals, such as physical therapists, can help you develop a personalized plan to strengthen your muscles and stabilize your joints. Pain management strategies, including medication and lifestyle changes, can also improve your quality of life. Remember, you are not alone, and support is available to help you navigate this condition.

1. Remvig L, Jensen DV, Ward RC. Epidemiology of general joint hypermobility and basis for the proposed criteria for benign joint hypermobility syndrome: review of the literature. J Rheumatol. 2007;34:804–9.
2. Kirk JA, Ansell BM, Bywaters EG. The hypermobility syndrome. Musculoskeletal complaints associated with generalized joint hypermobility. Ann Rheum Dis. 1967;26:419–25.
3. Simmonds JV, Keer RJ. Hypermobility and the hypermobility syndrome. Man. Ther. 2007;12:298–309.
4. Cattalini M, Khubchandani R, Cimaz R. When flexibility is not necessarily a virtue: a review of hypermobility syndromes and chronic or recurrent musculoskeletal pain in children. Pediatr Rheumatol Online J. 2015; 13:40
5. Simpson MR. Benign joint hypermobility syndrome: evaluation, diagnosis, and management. J Am Osteopath Assoc 2006;106:531-6.
6. Hakim AJ, Cherkas LF, Grahame R, Spector TD, MacGregor AJ. The genetic epidemiology of joint hypermobility: a population study of female twins. Arthritis Rheum. 2004;50:2640–2644.
7. Malfait F, Hakim AJ, De Paepe A, Grahame R. The genetic basis of the joint hypermobility syndromes. Rheumatology. 2006;45(5):502–7.
8. Beighton P, De Paepe A, Steinmann B, et al. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J. Med Genet. 1998 Apr 28;77 (1): 31-7
9. Hamonet C, Frédy D, Lefèvre JH, Bourgeois-Gironde S, Zeitoun JD. Brain injury unmasking Ehlers-Danlos syndromes after trauma: the fiber print. Orphanet J Rare Dis. 2016 Apr; 22. 11:45.